Guy P. Sansone
Guy P. Sansone's purchase track record
Guy P. Sansone has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/5/2025 | CVS | $100K | +18.1% | +24.0% | +15.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status. CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Brookdale Q3 Occupancy Misses Estimates, RBC Cuts Outlook. Brookdale Senior Living reported September 2026 occupancy results that fell short of analyst expectations, prompting RBC Capital Markets to note the disappointment. This news contrasts with a recent upgrade to Strong Buy, creating a mixed signal for investors. The stock is currently trading near its 52-week low, reflecting ongoing pressure on the valuation despite some positive operational updates.
Transaction History
| MD | ▲ Buy | Grant | 472 | $13K | 8/12/2026 | View on chart |
| CVS | ▲ Buy | Grant | 1,447 | $141K | 5/14/2026 | View on chart |
| MD | ▲ Buy | Grant | 7,196 | $0 | 5/7/2026 | View on chart |
| CVS | ▲ Buy | Grant | 1,652 | $126K | 11/20/2025 | View on chart |
| CVS | ▲ Buy | Open Market | 1,570 | $100K | 6/5/2025 | View on chart |
| CVS | ▲ Buy | Grant | 2,077 | $126K | 5/15/2025 | View on chart |
| MD | ▲ Buy | Grant | 11,427 | $0 | 5/8/2025 | View on chart |
| CVS | ▲ Buy | Grant | 2,200 | $126K | 11/21/2024 | View on chart |
| MD | ▲ Buy | Grant | 18,360 | $0 | 5/9/2024 | View on chart |
| BKD | ▲ Buy | Grant | 23,214 | $0 | 2/15/2024 | View on chart |
| MD | ▲ Buy | Grant | 10,965 | $0 | 5/11/2023 | View on chart |
| BKD | ▲ Buy | Grant | 45,763 | $0 | 2/15/2023 | View on chart |
| MD | ▲ Buy | Grant | 8,480 | $0 | 5/12/2022 | View on chart |
| BKD | ▲ Buy | Grant | 24,545 | $0 | 2/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
MD mentioned in list of stocks with questionable fundamentals
Pediatrix Medical Group (MD) was recently included in a Yahoo Finance article highlighting three unpopular stocks with questionable fundamentals. This mention draws attention to the company's valuation and financial metrics, placing it in a category that some market observers view with caution. The stock currently trades near its 52-week high range, with an average analyst target price of $26.33.
MD mentioned in list of stocks with questionable fundamentals. Pediatrix Medical Group (MD) was recently included in a Yahoo Finance article highlighting three unpopular stocks with questionable fundamentals. This mention draws attention to the company's valuation and financial metrics, placing it in a category that some market observers view with caution. The stock currently trades near its 52-week high range, with an average analyst target price of $26.33.